Practice Economics

Feds call for more transparency in reporting clinical trial results


 

References

A proposal is being floated to make clinical trial results posted to ClinicalTrials.gov more transparent, complete, and timely, regardless of whether the trial is related to an approved product.

The Department of Health & Human Services posted a proposed rule for public inspection on Nov. 19 that would expand the reporting requirements for ClinicalTrials.gov to include results on all clinical trials that are required to register on the trials database, not just results for drugs and devices that are approved, licensed, or cleared for use. It also expands data elements that are accessible and proposes more frequent updating for certain data.

Comments on the proposed rule are due within 90 days of its publication in the Federal Register on Nov. 21. ©Alexander Raths/Fotolia.com

Comments on the proposed rule are due within 90 days of its publication in the Federal Register on Nov. 21.

Other than phase I studies of drugs and biologics and small feasibility studies of devices, trials involving drugs and devices regulated by the Food and Drug Administration would be subject to the reporting requirement under this proposal, irrespective of who is funding the study.

A separate proposal by the National Institutes of Health would apply the expanded reporting proposal to all trials funded by NIH, regardless of whether those trials would otherwise not be required to report to ClinicalTrials.gov under requirements set in the FDA Amendments Act of 2007.

“The scientific community has a disappointing track record for dissemination of clinical trial results,” NIH Deputy Director for Science, Outreach and Policy Kathy Hudson, Ph.D., and Director Dr. Francis Collins wrote in a viewpoint published in JAMA (2014 Nov. 19 [doi:10.1001/jama.2014.10716]) .

The NIH officials noted that a “recent analysis of 400 clinical studies revealed that 30% had not shared results through publication or through results reporting in ClinicalTrials.gov within 4 years of completion. This is a serious issue and the proposed rule underscores the intent of NIH to take strong action to promote timely dissemination of clinical trial results.”

Comments on the proposed rule are due within 90 days of its publication in the Federal Register on Nov. 21. The response date for comments on the NIH draft policy on reporting requirements for NIH-funded studies is Feb. 19, 2015.

gtwachtman@frontlinemedcom.com

Recommended Reading

Proposed ACO rules allow time to grow before penalties
MDedge Dermatology
Spending on physician services shrunk again in 2013
MDedge Dermatology
CMS expands ability to deny provider enrollments
MDedge Dermatology
ONC strategic plan keeps focus on adoption, interoperability
MDedge Dermatology
EHRs: Incentives spurred adoption
MDedge Dermatology
Court: State cannot withhold Medicaid payments for program violations
MDedge Dermatology
Maintaining Adequate Third-Party Compensation
MDedge Dermatology
Physicians shun Stage 2 of meaningful use
MDedge Dermatology
Congress leaves SGR, Medicaid parity, ICD-10 undone
MDedge Dermatology
Stains and Smears: Resident Guide to Bedside Diagnostic Testing
MDedge Dermatology

Related Articles